Off-tumor target-beneficial site for antiangiogenic cancer therapy?
Off-tumor target-beneficial site for antiangiogenic cancer therapy?
复制标题
DOI：
10.1038/nrclinonc.2010.118
复制
发表时间：
2010-10-01
影响因子：
78.8
通讯作者：
Cao, Yihai
中科院分区：
文献类型：
--
作者：
Cao, Yihai
抗血管生成癌症治疗是基于靶向肿瘤血管抑制其生长的药物。然而，临床经验表明，抗血管生成治疗后的生存益处并不总是与肿瘤大小和生长抑制相关。新出现的证据表明，抗血管生成药物的递送可能会引起血管系统的系统性改变，从而调节各种组织和器官的功能。通过抗血管生成治疗使组织和器官正常化可能是癌症相关系统性综合征患者生存获益的重要机制。这一新概念已在临床前肿瘤模型中得到验证，患者的反应与临床获益呈正相关。
Antiangiogenic cancer therapy is based on agents that target blood vessels of the tumor to inhibit its growth. However, experience from the clinic demonstrates that survival benefits following antiangiogenic therapy do not always correlate with tumor size and growth inhibition. Emerging evidence shows that delivery of antiangiogenic drugs might induce systemic alterations of the vasculature that modulate the function of various tissues and organs. Normalization of tissues and organs by antiangiogenic therapy may be an important mechanism underlying the survival benefits seen in patients with cancer who suffer cancer-associated systemic syndromes. This new concept has been validated in preclinical tumor models, and responses in patients have positively correlated with clinical benefits.